Profile data is unavailable for this security.
About the company
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
- Revenue in USD (TTM)23.13m
- Net income in USD-51.81m
- Incorporated1994
- Employees115.00
- LocationSilence Therapeutics PLC72 Hammersmith RoadLONDON W14 8THUnited KingdomGBR
- Phone+44 203 457 6900
- Fax+44 795 731 8494
- Websitehttps://www.silence-therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOAGE Labs Inc | 0.00 | -62.16m | 758.17m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Perspective Therapeutics Inc | -1.87m | -49.02m | 758.56m | 116.00 | -- | 2.22 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
| Annexon Inc | 0.00 | -115.16m | 763.88m | 71.00 | -- | 2.11 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| IGM Biosciences Inc | 2.91m | -220.40m | 772.92m | 204.00 | -- | 6.31 | -- | 265.52 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 783.51m | 40.00 | -- | 6.04 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 792.31m | 267.00 | -- | -- | -- | 2.09 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| AbCellera Biologics Inc | 32.96m | -175.80m | 797.49m | 586.00 | -- | 0.7284 | -- | 24.19 | -0.5999 | -0.5999 | 0.1125 | 3.71 | 0.0227 | -- | 0.958 | 56,250.85 | -12.10 | 6.08 | -12.95 | 6.67 | -- | -- | -533.32 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Immunome Inc | 10.78m | -262.59m | 808.46m | 55.00 | -- | 3.07 | -- | 74.97 | -5.64 | -5.64 | 0.2591 | 4.23 | 0.0639 | -- | -- | 196,072.70 | -155.54 | -94.54 | -193.54 | -112.66 | -- | -- | -2,435.02 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Silence Therapeutics PLC - ADR | 23.13m | -51.81m | 817.48m | 115.00 | -- | 5.64 | -- | 35.34 | -1.25 | -1.25 | 0.5543 | 3.11 | 0.1273 | -- | 2.56 | 201,130.40 | -28.51 | -- | -32.89 | -- | 56.40 | -- | -224.01 | -- | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | -- | -- |
| Zenas Biopharma Inc | 50.00m | -54.76m | 835.64m | 114.00 | -- | -- | -- | 16.71 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -220.01m | 849.92m | 331.00 | -- | 1.99 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Tyra Biosciences Inc | 0.00 | -80.88m | 850.71m | 49.00 | -- | 2.26 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Dianthus Therapeutics Inc | 4.12m | -56.68m | 853.39m | 53.00 | -- | 2.38 | -- | 207.23 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Adaptive Biotechnologies Corp | 168.77m | -213.47m | 858.29m | 709.00 | -- | 3.55 | -- | 5.09 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Capricor Therapeutics Inc | 27.15m | -27.95m | 881.46m | 101.00 | -- | 54.78 | -- | 32.46 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Data as of Nov 08 2024. Currency figures normalised to Silence Therapeutics PLC's reporting currency: US Dollar USD
29.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 25 Jul 2024 | 2.78m | 5.96% |
| Lombard Odier Asset Management (USA) Corp.as of 30 Jun 2024 | 2.41m | 5.16% |
| Redmile Group LLCas of 30 Jun 2024 | 2.01m | 4.32% |
| Logos Global Management LPas of 30 Jun 2024 | 1.48m | 3.16% |
| Deep Track Capital LPas of 30 Jun 2024 | 1.36m | 2.91% |
| Polar Capital LLPas of 30 Jun 2024 | 940.16k | 2.02% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 818.98k | 1.76% |
| Millennium Management LLCas of 30 Jun 2024 | 782.94k | 1.68% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 625.00k | 1.34% |
| Adage Capital Management LPas of 30 Jun 2024 | 600.00k | 1.29% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
